**A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)** is examining a treatment for MSA, a rare disorder affecting the brain's movement and balance control. Participants will receive a nasal spray medicine called Foralumab. To join, you must be between 30 to 85 years old and have a confirmed MSA diagnosis. The study requires stable medical conditions and specific blood test results. Some people can't join, like those with other brain conditions, pregnant women, or those with severe heart issues. You also shouldn’t have certain treatments or infections recently. This study involves multiple visits and tests to check safety and effectiveness. **Key Points:** - **Study Duration:** Participation involves several visits over a few months. - **Eligibility:** Specific health criteria must be met to ensure safety. - **Compensation:** Potential monetary or non-monetary compensation may be provided for participation. If you're interested, discuss with your doctor to see if you qualify and understand the potential benefits and risks. It's essential to be comfortable with nasal medication and follow all study procedures.